Last updated: October 6, 2026
Meperidine hydrochloride preservative-free is a mature, generic injectable opioid with declining long-term demand, limited pricing power, and low patent risk. Its commercial value is concentrated in hospital formularies, emergency-care supply, anesthesia-related use, and shortage-driven purchasing. Public sources do not disclose product-level revenue, market share, or manufacturer profitability for the preservative-free presentation. The financial trajectory is therefore best assessed through volume, pricing, regulatory, supply-chain, and opioid-stewardship trends rather than a verified revenue series.
What is the FDA status of preservative-free meperidine hydrochloride?
Preservative-free meperidine hydrochloride is an injectable formulation of meperidine, an opioid analgesic indicated for the management of pain severe enough to require an opioid when alternative treatments are inadequate. The product is administered parenterally and is available in several labeled strengths, depending on the manufacturer and presentation.
Meperidine products are approved prescription drugs and are subject to the FDA’s opioid labeling requirements. The prescribing information includes boxed warnings addressing respiratory depression, misuse, abuse, addiction, and risks associated with concomitant use of benzodiazepines or other central nervous system depressants. Meperidine also has specific safety concerns involving normeperidine, an active metabolite associated with neurotoxicity and seizures, particularly with repeated dosing or renal impairment.
The drug is a Schedule II controlled substance in the United States. That classification increases compliance, inventory-control, security, recordkeeping, and distribution costs relative to noncontrolled hospital injectables. The Controlled Substances Act scheduling framework is administered by the Drug Enforcement Administration (DEA). (U.S. Food and Drug Administration, n.d.-a; DEA, n.d.)
What does “preservative-free” mean commercially?
Preservative-free meperidine hydrochloride is generally supplied in single-dose vials, ampules, or other unit-dose injectable presentations. The absence of antimicrobial preservatives is relevant to formulation, container selection, storage, and hospital medication-use policies.
The presentation is not a separate active pharmaceutical ingredient. It is a formulation and packaging distinction within the broader meperidine hydrochloride injectable market. Commercial demand depends on institutional requirements, availability of specific vial sizes, compatibility with hospital workflows, and procurement contracts.
When does meperidine hydrochloride lose exclusivity?
Meperidine hydrochloride lost meaningful composition-of-matter patent protection decades ago. The active ingredient is a legacy small molecule, and the U.S. market is supplied through generic applications and legacy branded or authorized-generic products.
No commercially important composition patent is expected to prevent generic competition. Any remaining intellectual-property value would be associated with narrow formulation, container, manufacturing, or use claims rather than exclusivity over meperidine itself.
| Exclusivity category |
Commercial status |
| Active-ingredient patent |
Expired or commercially irrelevant |
| New chemical entity exclusivity |
Expired |
| Formulation exclusivity |
No broad market-blocking exclusivity identified in public product records |
| Method-of-use exclusivity |
Limited practical relevance for standard injectable analgesia |
| Orphan-drug exclusivity |
Not applicable to the conventional product |
| Biosimilar exclusivity |
Not applicable because meperidine is a small-molecule drug |
| Generic competition |
Established |
The FDA Orange Book identifies approved drug products and patent or exclusivity information submitted for listed products. A product-level Orange Book review is necessary to confirm any current listing tied to a particular NDA or ANDA, but the drug’s commercial profile does not indicate an active patent barrier capable of delaying ordinary generic competition. (U.S. Food and Drug Administration, n.d.-b)
How many patents cover preservative-free meperidine hydrochloride?
Publicly relevant patent protection is limited. The drug’s core patent estate is expired, and preservative-free injectable products generally compete on manufacturing reliability, regulatory status, packaging, quality systems, and distribution rather than on active patent claims.
What formulations are protected?
Potential technical claim areas can include:
- Sterile injectable composition and concentration
- Container-closure systems
- Ampule or vial configuration
- Manufacturing and sterilization processes
- Stability profiles
- Label-specific administration or dosing instructions
These claim categories rarely create durable commercial exclusivity for a mature generic injectable unless they are tied to a difficult-to-reproduce formulation or an approved product with no practical substitute. For meperidine hydrochloride, the principal competitive barriers are more likely to be regulatory compliance and supply continuity than patent enforcement.
What is the Orange Book status of meperidine hydrochloride injection?
Meperidine hydrochloride injection is represented in FDA-approved product databases through individual branded, generic, and abbreviated new drug applications. The exact Orange Book status varies by product holder, dosage strength, route, and approval pathway.
The relevant distinction is between:
- The reference-listed drug or legacy branded product.
- ANDA-approved generic injectable products.
- Products that remain approved but may have limited commercial distribution.
- Products listed as discontinued for commercial reasons rather than withdrawn for safety or efficacy.
A discontinued listing does not automatically establish that the underlying drug is unavailable. Hospital purchasing data, wholesaler listings, and FDA shortage information are needed to determine active supply for each manufacturer and strength. (U.S. Food and Drug Administration, n.d.-b; U.S. Food and Drug Administration, n.d.-c)
What is the market size and financial trajectory?
Public companies generally do not report revenue for preservative-free meperidine hydrochloride as a standalone product. The product is usually included within broader hospital injectable, generic pharmaceutical, or contract-manufacturing revenue lines.
The financial trajectory is structurally mature to declining:
| Driver |
Directional effect on revenue |
| Opioid stewardship |
Negative |
| Substitution by morphine, hydromorphone, fentanyl, and nonopioid analgesics |
Negative |
| Established generic competition |
Negative for price |
| Hospital demand for injectable products |
Supports baseline volume |
| Supply disruptions among competitors |
Can create temporary price increases |
| Controlled-substance compliance |
Raises cost |
| Limited patent protection |
Prevents premium pricing |
| Legacy clinical use |
Supports residual demand |
Meperidine has lost share in many clinical settings because of normeperidine accumulation, seizure risk, renal-clearance concerns, and the availability of opioids with more favorable pharmacokinetic or formulary profiles. Several hospitals restrict or remove meperidine from routine pain protocols except for narrow indications such as selected treatment of postoperative shivering, depending on institutional policy.
Revenue can still rise temporarily during a shortage affecting substitute injectable opioids or competing meperidine suppliers. That increase would generally represent price and allocation effects rather than durable demand expansion.
Which companies compete in the meperidine hydrochloride injection market?
Competition is fragmented across generic injectable manufacturers, specialty pharmaceutical suppliers, and hospital-distribution channels. Public product records have historically included manufacturers and labelers such as Pfizer legacy products, Hikma Pharmaceuticals, Fresenius Kabi, and other generic suppliers, although active commercial availability varies by strength, packaging, and time.
Manufacturer-level analysis must distinguish between:
- Approval ownership
- Current labeler
- Actual commercial supply
- Contract manufacturing
- Wholesaler distribution
- Temporary or permanent discontinuation
A company may retain an approved application while selling limited quantities or suspending routine distribution. That distinction is material for procurement and revenue analysis.
What generic entry risks exist?
Generic entry risk is already realized rather than prospective. The market has long had generic competition, so a new entrant would not create the first competitive shock. Its principal effects would be:
- Lower contract prices
- Greater hospital bargaining power
- Increased tender competition
- Possible inventory substitution
- Pressure on incumbent manufacturing utilization
The main launch barrier is not patent clearance. It is commercial viability. A new supplier must support sterile manufacturing, controlled-substance compliance, validated container systems, quality assurance, pharmacovigilance, and reliable distribution. Low annual demand can make the product unattractive unless the manufacturer has an existing injectable platform and shared production economics.
What patent litigation affects meperidine hydrochloride?
No major current patent litigation is commercially associated with conventional preservative-free meperidine hydrochloride injection in the public record. The absence of litigation is consistent with the drug’s age, generic status, and limited remaining exclusivity.
Paragraph IV challenges are unlikely to have material strategic significance because the market is already genericized. Any ANDA litigation would more likely involve a narrow formulation or manufacturing patent and would not ordinarily protect the active ingredient from competition.
Are there settlement agreements involving meperidine hydrochloride?
No commercially significant patent settlement agreement is associated with the conventional preservative-free meperidine hydrochloride market in widely used public regulatory and litigation records. Legacy opioid settlements and broader opioid litigation concern distribution, marketing, public-health damages, and compliance issues rather than a product-specific patent settlement protecting injectable meperidine.
How strong is the patent estate for preservative-free meperidine?
The patent estate is weak from a market-exclusivity perspective.
| Patent-strength factor |
Assessment |
| Core molecule |
Weak; legacy protection expired |
| Injectable formulation |
Potentially narrow |
| Preservative-free presentation |
Limited exclusivity potential |
| Manufacturing process |
Possible technical protection, usually nonblocking |
| Method of use |
Narrow and clinically constrained |
| Litigation leverage |
Low |
| Generic launch exposure |
High |
| Geographic reach |
Primarily dependent on national approvals |
The product’s defensibility comes from execution rather than intellectual property. The strongest commercial positions belong to suppliers with approved sterile capacity, dependable raw-material sourcing, hospital contracts, and a record of avoiding supply interruptions.
How does meperidine compare with competing injectable opioids?
| Product |
Commercial position |
Key competitive issue |
| Meperidine injection |
Mature, declining niche |
Normeperidine toxicity and restricted hospital use |
| Morphine injection |
Broad hospital use |
Established standard with extensive generic supply |
| Hydromorphone injection |
Stronger position in severe pain settings |
Higher potency and controlled-substance handling |
| Fentanyl injection |
Broad procedural and anesthesia use |
High potency and intensive control requirements |
| Nonopioid injectable analgesics |
Substitution opportunity |
Supports opioid-sparing protocols |
Meperidine is generally less favored for routine pain management than morphine, hydromorphone, or fentanyl. Its remaining demand is more sensitive to formulary policy and local clinical preference than demand for the leading injectable opioids.
What manufacturing and supply barriers affect the market?
Sterile injectable manufacturing is the principal barrier. Manufacturers must manage:
- Aseptic processing and environmental control
- Sterility assurance
- Container-closure integrity
- Extractables and leachables
- Controlled-substance inventories
- Batch-release testing
- Drug-supply-chain security requirements
- FDA inspection and quality-system obligations
Supply risk can be disproportionate to market size. A small number of active suppliers, low production volumes, and hospital purchasing contracts can produce temporary shortages even when aggregate national demand is modest. FDA shortage records and manufacturer notices are the relevant sources for current availability. (U.S. Food and Drug Administration, n.d.-c)
What is the outlook for sales and investment value?
The base case is low-growth or declining volume with intermittent pricing volatility. A supplier can generate stable niche cash flow if it maintains an approved product, controls manufacturing costs, and secures institutional contracts. The product is unlikely to support material long-term revenue expansion without a broader injectable portfolio or a supply disruption affecting alternatives.
The most relevant financial indicators are:
- Number of active suppliers by strength and package size.
- FDA shortage status.
- Hospital formulary restrictions.
- Contract renewal pricing.
- Manufacturing utilization.
- Product discontinuation notices.
- Share of revenue within the manufacturer’s injectable portfolio.
- Cost of controlled-substance compliance and quality remediation.
Standalone valuation based on meperidine revenue is not supportable from public disclosures. The product is more relevant as a portfolio filler, hospital-contract product, or supply-continuity asset than as a high-growth pharmaceutical franchise.
Key Takeaways
- Preservative-free meperidine hydrochloride is a mature generic injectable opioid with declining clinical demand.
- Core patent protection is expired, and no meaningful patent barrier is expected to block generic competition.
- Product-level revenue and market-share data are generally not publicly disclosed.
- The main commercial risks are substitution, hospital formulary restrictions, low pricing power, and supply interruptions.
- The main operational advantage is reliable sterile manufacturing and distribution.
- Biosimilar risk does not apply because meperidine is a small-molecule drug.
- Patent litigation and Paragraph IV activity are not material features of the current market.
- Financial performance is likely to be stable only in a narrow niche, with temporary upside during competitor shortages.
FAQs
Is preservative-free meperidine hydrochloride still commercially available?
Availability depends on manufacturer, strength, package size, and current supply conditions. FDA shortage records and wholesaler data provide the most relevant product-specific status.
Does meperidine hydrochloride have active U.S. patent protection?
No broad active patent protection is expected to cover the legacy active ingredient. Any surviving claims would likely be narrow formulation, manufacturing, or packaging claims.
Can a generic manufacturer launch preservative-free meperidine without Paragraph IV litigation?
A launch depends on the specific reference product, listed patents, and ANDA certification. Given the drug’s mature generic status, patent-based launch restrictions are generally limited.
Is meperidine hydrochloride a biologic or biosimilar product?
No. Meperidine hydrochloride is a synthetic small-molecule opioid and is regulated through the conventional drug approval framework rather than the biosimilar pathway.
What would increase the value of a meperidine injection product?
Value would primarily increase through supply scarcity, an approved sterile manufacturing platform, hospital contracts, reliable controlled-substance distribution, or portfolio synergies with other injectable products.
References
-
Drug Enforcement Administration. (n.d.). Drug scheduling. https://www.dea.gov/drug-information/drug-scheduling
-
U.S. Food and Drug Administration. (n.d.-a). Meperidine hydrochloride injection prescribing information. https://www.accessdata.fda.gov
-
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (n.d.-c). Drug shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
-
U.S. Food and Drug Administration. (n.d.-d). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
